Human Genome Epidemiology Literature Finder
Records 1 - 27 (of 27 Records) |
Query Trace: Drug-Induced Liver Injury and NAT2[original query] |
---|
Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2008 Sep 12 (9): 994-1002. Sun F, Chen Y, Xiang Y, Zhan |
[The associations of polymorphism of N-acetyltransferase 2 gene is associated with antituberculosis drug-induced hepatotoxicity in tuberculosis patients]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 2011 Jan 45 (1): 36-40. An Hui-ru, Wu Xue-qiong, Wang Zhong-yuan, Liang Yan, Zhang Jun-xi |
NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2012 May 16 (5): 589-95. Wang P-Y, Xie S-Y, Hao Q, Zhang C, Jiang B |
Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PloS one 2012 7 (10): 10. Cai Y, Yi J, Zhou C, Shen X |
N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. European journal of clinical pharmacology 2014 Sep 70 (9): 1079-86. Ng Ching-Soon, Hasnat Abul, Al Maruf Abdullah, Ahmed Maizbha Uddin, Pirmohamed Munir, Day Christopher P, Aithal Guruprasad P, Daly Ann |
The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1. PloS one 2014 9 (1): e85905. Xiang Yang, Ma Long, Wu Weidong, Liu Wei, Li Yongguang, Zhu Xia, Wang Qian, Ma Jinfeng, Cao Mingqin, Wang Qian, Yao Xuemei, Yang Lei, Wubuli Atikaimu, Merle Corinne, Milligan Paul, Mao Ying, Gu Jiayi, Xin Xium |
Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis. Pharmacogenomics 2015 Nov . Shi Jing, Xie Min, Wang Jianmiao, Xu Yongjian, Liu Xianshe |
Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients. Human genome variation 2016 3 16014. Mushiroda Taisei, Yanai Hideki, Yoshiyama Takashi, Sasaki Yuka, Okumura Masao, Ogata Hideo, Tokunaga Katsus |
NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. Journal of human genetics 2016 Jun 61 (6): 533-7. Yuliwulandari Rika, Susilowati Retno Wilujeng, Wicaksono Britanto Dani, Viyati Kencono, Prayuni Kinasih, Razari Intan, Kristin Erna, Syafrizal , Subagyo , Sri Diana Eva, Setiawati Suci, Ariyani Aziza, Mahasirimongkol Surakameth, Yanai Hideki, Mushiroda Taisei, Tokunaga Katsus |
NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2016 Oct 20 (10): 1364-1369. Wattanapokayakit S, Mushiroda T, Yanai H, Wichukchinda N, Chuchottawon C, Nedsuwan S, Rojanawiwat A, Denjanta S, Kantima T, Wongyai J, Suwankesawong W, Rungapiromnan W, Kidkeukarun R, Bamrungram W, Chaiwong A, Suvichapanich S, Mahasirimongkol S, Tokunaga |
Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. PloS one 2017 12 (10): e0186200. Chan Sze Ling, Chua Angeline Poh Gek, Aminkeng Folefac, Chee Cynthia Bin Eng, Jin Shengnan, Loh Marie, Gan Suay Hong, Wang Yee Tang, Brunham Liam |
The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. British journal of clinical pharmacology 2018 Jul . Zhang Min, Wang Shuqiang, Wilffert Bob, Tong Rongsheng, van Soolingen Dick, van den Hof Susan, Alffenaar Jan-Will |
NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis. Pharmacogenetics and genomics 2018 Jul 28 (7): 167-176. Suvichapanich Supharat, Fukunaga Koya, Zahroh Hilyatuz, Mushiroda Taisei, Mahasirimongkol Surakameth, Toyo-Oka Licht, Chaikledkaew Usa, Jittikoon Jiraphun, Yuliwulandari Rika, Yanai Hideki, Wattanapokayakit Sukanya, Tokunaga Katsus |
Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients. International journal of mycobacteriology 0 7 (4): 380-386. Perwitasari Dyah Aryani, Darmawan Endang, Mulyani Ully Adhi, Vlies Pieter Van Der, Alffenaar Jan-Willem C, Atthobar Jarir, Wilffert B |
Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis. BMJ open 2019 Aug 9 (8): e027940. Yang Seungwon, Hwang Se Jung, Park Jung Yun, Chung Eun Kyoung, Lee Jangik |
Genomewide Association Study Confirming the Association of NAT2 with Susceptibility to Antituberculosis Drug-Induced Liver Injury in Thai Patients.
![]() Antimicrobial agents and chemotherapy 2019 Aug 63 (8): . Suvichapanich Supharat, Wattanapokayakit Sukanya, Mushiroda Taisei, Yanai Hideki, Chuchottawon Charoen, Kantima Tassawan, Nedsuwan Supalert, Suwankesawong Wimon, Sonsupap Cholticha, Pannarunothai Roongkarn, Tumpattanakul Sukanya, Bamrungram Warawut, Chaiwong Achara, Mahasirimongkol Surakameth, Mameechai Sasithorn, Panthong Weerapat, Klungtes Nantawan, Munsoo Amara, Chauychana Udomrat, Maneerat Molrudee, Fukunaga Koya, Omae Yosuke, Tokunaga Katsus |
The role of NAT2 polymorphism and methylation in anti-tuberculosis drug-induced liver injury in Mongolian tuberculosis patients. Journal of clinical pharmacy and therapeutics 2020 Jun 45 (3): 561-569. Zhang Dong, Hao Jinqi, Hou Ruili, Yu Yanqin, Hu Baocui, Wei Liq |
Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens.
![]() Clinical pharmacology and therapeutics 2020 11 109 (4): 1125-1135. Nicoletti Paola, Devarbhavi Harshad, Goel Ashish, Venkatesan Radha, Eapen Chundamannil E, Grove Jane I, Zafer Samreen, Bjornsson Einar, Lucena M Isabel, Andrade Raul J, Pirmohamed Munir, Wadelius Mia, Larrey Dominique, Maitland-van der Zee Anke-Hilse, Ibanez Luisa, Watkins Paul B, Daly Ann K, Aithal Guruprasad |
Genetic characterization of N-acetyltransferase 2 variants in acquired multidrug-resistant tuberculosis in Indonesia. Pharmacogenomics 2021 1 22 (3): 157-163. Yuliwulandari Rika, Prayuni Kinasih, Razari Intan, Susilowati Retno W, Zulhamidah Yenni, Soedarsono Soedarsono, Sofro Abdul Salam M, Tokunaga Katsus |
NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients. Molecular genetics & genomic medicine 2022 Jun e1987. Jaramillo-Valverde Luis, Levano Kelly S, Tarazona David D, Capristano Silvia, Zegarra-Chapoñan Roberto, Sanchez Cesar, Yufra-Picardo Velia M, Tarazona-Santos Eduardo, Ugarte-Gil Cesar, Guio Heinn |
Clinical and Genetic Risk Factors for Drug-Induced Liver Injury Associated with Anti-Tuberculosis Treatment-A Study from Patients of Portuguese Health Centers. Journal of personalized medicine 2022 May 12 (5): . Cavaco Maria João, Alcobia Celeste, Oliveiros Bárbara, Mesquita Luís Alcides, Carvalho Aurora, Matos Fernando, Carvalho José Miguel, Villar Miguel, Duarte Raquel, Mendes João, Ribeiro Carolina, Cordeiro Carlos Robalo, Regateiro Fernando, Silva Henriqueta Coimb |
GSTT1/GSTM1 Genotype and Anti-Tuberculosis Drug-Induced Hepatotoxicity in Peruvian Patients. International journal of molecular sciences 2022 10 23 (19): . Jaramillo-Valverde Luis, Levano Kelly S, Tarazona David D, Vasquez-Dominguez Andres, Toledo-Nauto Anel, Capristano Silvia, Sanchez Cesar, Tarazona-Santos Eduardo, Ugarte-Gil Cesar, Guio Heinn |
N-acetyltransferase 2 genetic polymorphisms and anti-tuberculosis-drug-induced liver injury: a correlation study. Frontiers in pharmacology 2023 9 14 1171353. Fang Cheng, Xian-Gao Jiang, Shi-Lin Zheng, Te Wu, Qiang Zhang, Xin-Chun Ye, Saiduo Liu, Ji-Chan S |
Relevance of NAT2 genotype and clinical factors to risk for antituberculosis drug-induced liver injury. Pharmacogenomics 2023 12 . Fang Cheng, Chao-Chao Qiu, Xian-Gao Jiang, Te Wu, Qiang Zhang, Xin Chen, Shi-Lin Zheng, Sai-Duo Liu, Xin-Chun Ye, Ji-Chan S |
N-acetyltransferase Gene Variants Involved in Pediatric Idiosyncratic Drug-Induced Liver Injury. Biomedicines 2024 6 12 (6): . María Luisa Alés-Palmer, Francisco Andújar-Vera, Iván Iglesias-Baena, Paloma Muñoz-de-Rueda, Esther Ocete-Hi |
Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations. Pharmacology research & perspectives 2024 4 12 (3): e1179. Luis Jaramillo-Valverde, Kelly S Levano, David D Tarazona, Silvia Capristano, Cesar Sanchez, Julio A Poterico, Eduardo Tarazona-Santos, Heinner Gu |
Influence of N-acetyltransferase 2 polymorphisms and clinical variables on liver function profile of tuberculosis patients. Expert review of clinical pharmacology 2024 1 1-12. Levin Thomas, Arun Prasath Raju, S Chaithra, Shrivathsa Kulavalli, Muralidhar Varma, Chidananda Sanju Sv, Mithu Baneerjee, Kavitha Saravu, Surulivelrajan Mallayasamy, Mahadev R |
- Page last reviewed:Feb 1, 2024
- Content source: